Researchers have developed an artificial intelligence (AI) model to predict kidney cancer patient responses to immunotherapy. The study, conducted by scientists at Memorial Sloan Kettering Cancer Center (MSKCC) and the National Institutes of Health (NIH), identified new biomarkers that can forecast the benefits of immune checkpoint blockade in advanced renal cell carcinoma patients. The AI tool, known as LORIS, uses clinical data to estimate the likelihood of a patient responding to immune checkpoint inhibitors, a type of immunotherapy drug that helps immune cells kill cancer cells. The findings were published by NIH and MSKCC researchers.
Researchers at MSK & @theNCI have developed a potential #AI tool using clinical data to predict whether someone’s #cancer will respond to immune checkpoint inhibitors, a type of #immunotherapy drug that helps immune cells kill cancer cells. Learn more ⬇️ https://t.co/ulSx5lXHdy
Scientists have shown that their LORIS artificial intelligence tool estimates the predictive likelihood of a patient responding to immune checkpoint inhibitors. Read more: https://t.co/eaXkZk2Puu https://t.co/CdJItDnieq
Check out the latest blog post on predicting immunotherapy responses using an AI model, published by NIH and MSKCC researchers. Stay updated with the latest advancements in cancer research. Read more at https://t.co/YigRog0CYX
Machine Learning Predicts Kidney Cancer Patient Responses to Immunotherapy Researchers discovered new biomarkers for predicting immune checkpoint blockade-driven benefits in advanced renal cell carcinoma patients. Learn more: https://t.co/jLfcgtsj2k https://t.co/wZVX9e5wiD
Scientists develop AI tool to predict how #cancer patients will respond to immunotherapy @NIHforHealth @naturecancer https://t.co/lbFzOYmA1r